Lithium and Alzheimer's: what contradictory data reveals about the LATTICE trial

The LATTICE trial, designed to validate lithium as a neuroprotective agent against cognitive decline, failed to meet its primary endpoint, forcing a critical reassessment of one of longevity's most studied molecules. Researchers enrolled participants at Alzheimer's risk and monitored cognitive progression markers throughout the study period, yet results showed no benefit matching the preclinical promise and observational data that had animated earlier enthusiasm. Yet trial failure does not foreclose the question: lithium's neuroprotective effects in animal models remain robust, and the specific doses, durations, and participant cohorts studied may not have captured the correct therapeutic window. For readers pursuing cognitive optimization, this underscores an uncomfortable but essential lesson: preclinical promise rarely translates linearly into clinical benefit, and intellectual humility in the face of contradictory data proves more valuable than premature certainty.